Clinical trial
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without…
NCT00321100 · Fox Chase Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00321100 |
|---|---|
| Title | Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab |
| Official title | Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | bevacizumab, cetuximab, Oxaliplatin, Capecitabine |
| Enrollment | 23 |
| Start date | Apr 12, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Dec 18, 2013 |
| First posted | May 3, 2006 |
| Last update posted | Jan 12, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: